M. Shi

发表

Blockade of AIM2 inflammasome or α1-AR ameliorates IL-1β release and macrophage-mediated immunosuppression induced by CAR-T treatment

Yuchen Liu, Xuan Zhao, Junnian Zheng, 2021, Journal for ImmunoTherapy of Cancer.

Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma

Kailin Xu, L. Zeng, Jiang Cao, 2022, Frontiers in Immunology.

Potent anti‐leukemia activities of humanized CD19‐targeted Chimeric antigen receptor T (CAR‐T) cells in patients with relapsed/refractory acute lymphoblastic leukemia

J. Zhao, Junnian Zheng, Huizhong Li, 2018, American journal of hematology.

Tumour-associated macrophages enhance breast cancer malignancy via inducing ZEB1-mediated DNMT1 transcriptional activation

Zhongwei Li, Ming Shi, H. Yong, 2022, Cell & Bioscience.

CRISPR screen in mechanism and target discovery for cancer immunotherapy

Xuan Zhao, Junnian Zheng, Shuci Liu, 2020 .

Expression of CHPF modulates cell proliferation and invasion in lung cancer

Junnian Zheng, Chengsong Cao, Jing Zhao, 2020, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

Neural regulation of drug resistance in cancer treatment.

Junnian Zheng, Zhongwei Li, Dan Liu, 2019, Biochimica et biophysica acta. Reviews on cancer.

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades

Xuan Zhao, Rui Hou, Dan Liu, 2022, Frontiers in Immunology.

Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma

Yuekun Qi, A. Liang, K. Qi, 2022, Frontiers in Immunology.

Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment

Hong Liu, Junnian Zheng, J. Qiao, 2021, Frontiers in Immunology.

Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma

Huizhong Li, Gang Wang, Kailin Xu, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.

Junnian Zheng, Gang Wang, J. Zhao, 2019, The Lancet. Haematology.

ATPIF1 inactivation promotes antitumor immunity through metabolic reprogramming of CD8+ T cells

Jianping Ye, Xiaoying Zhang, Yinming Liang, 2020, bioRxiv.

Safety and efficacy of a humanized CD19 chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia

R. Gale, Junnian Zheng, Huizhong Li, 2022, American journal of hematology.

Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma

Bing Zhang, Junnian Zheng, Kailin Xu, 2020, Cancer medicine.

Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma

Junnian Zheng, Jianfeng Zhou, A. Liang, 2021, Blood advances.

Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection

R. Gale, Junnian Zheng, Xi Zhang, 2020, Leukemia.

Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia

Hui Gao, Junnian Zheng, Kailin Xu, 2021, Journal of cellular and molecular medicine.

Coagulation Disorders after CAR T Cell Therapy: Analysis of 100 Patients with R/R Hematologic Malignancies.

Junnian Zheng, K. Qi, J. Qiao, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Humanized CD19-specific chimeric antigen-receptor T-cells in 2 adults with newly diagnosed B-cell acute lymphoblastic leukemia

Junnian Zheng, Huizhong Li, Gang Wang, 2019, Leukemia.

Efficacy and safety of CD19-specific CAR T cell–based therapy in B-cell acute lymphoblastic leukemia patients with CNSL

He Huang, Yuekun Qi, Jianfeng Zhou, 2022, Blood.

Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma.

Yuekun Qi, K. Qi, Kailin Xu, 2023, Cytotherapy.

Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy

Junnian Zheng, Kailin Xu, Jiang Cao, 2021, Frontiers in Immunology.

Kinetics of immune reconstitution after anti‐CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients

Junnian Zheng, K. Zhao, K. Qi, 2020, International journal of laboratory hematology.

Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma

J. Qiao, Kailin Xu, L. Zeng, 2022, Frontiers in Immunology.